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 Abstract - Angioplasty with drug-coated balloon 
(DCB) is an emerging and reliable method for the 
treatment of femoro-popliteal lesions. We report 
our experience with the Stellarex™ DCB in the 
first 50 patients.                                                             
Methods - From July 2015 to November 2017, 50 
patients (41 M, 9F), medium age (64 ± 7.4 year) 
were subject to 33 angioplasties (PTAs) for 
femoro-popliteal lesions with a paclitaxel-coated 
balloon (Stellarex™). Based upon clinical data 
sixteen patients had severe claudication (56% - 
Rutherford class 3); ten patients suffered from 
ischemic rest pain (34% - Rutherford class 4); and 
five presented minor tissue loss (10% - 
Rutherford class 5). 42% of patients showed 
femoro-popliteal lesion TASC-II B, and 58% 
presented lesions pertaining to TASC-II C.  
Results - Immediate technical success was 100% 
without perioperative complications. Primary 
patency rate was 94% at twelve months. In three 
cases restenosis (6%) was detected within a year 
from procedure, and a further PTA DCB was 
performed with primary assisted patency rates of 
100% at twelve months. Two patients underwent 
major lower limb amputation. Three patients died 
during follow-up and one patient was lost at 
follow-up.                                                               
Conclusion - DCB angioplasty with Stellarex™ 
is a viable alternative to traditional endovascular 
procedures proving satisfactory primary patency 
rates at twelve months. Based on our experience, 
treatment with DCB is a first choice technique for 
non-complex de novo lesions of the femoro – 
popliteal tract. 
 
Keywords: drug-coated balloon; peripheral arterial 





I.  INTRODUCTION 
 
In peripheral artery disease, endovascular 
treatment with percutaneous transluminal 
angioplasty is considered a primary option 
however probability of restenosis within the first 
6 - 12 months after treatment (1,2) is higher than 
with stenting or drug coated-balloons as 
demonstrated in a number of previous trials (3-6). 
Balloon inflation can cause an injury in the 
vascular wall, which may subsequently trigger 
immediate elastic recoil, intimal dissection and 
negative vascular remodeling by neointimal 
hyperplasia. Nitinol stenting can prevent elastic 
recoil and dissection and risk of early occlusion 
thereafter, however it cannot inhibit neo-intimal 
hyperplasia. Treatment with drug-eluting stents is 
surely a promising improvement yet presents 
intrinsic limits on stent implantation such as the 
presence of a foreign body, risk of fracture and 
difficult treatment in cases of in-stent restenosis. 
Drug Coated Balloon (DCB) provides the 
possibility to treat target lesions by way of local 
drug release with no foreign bodies left behind. 
Given these advantages, the purpose of our study 
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was to assess short and medium term 
effectiveness as well as safety of DCB treatment.  
 
 
II.  METHODS 
 
Our study was a retrospective, single – arm and 
single center study in which patients underwent 
femoro-popliteal angioplasties with the 
Stellarex™ coated balloon (Spectranetics Corp., 
Colorado Springs, CO); a 0.035″ compatible 
over-the-wire device coated with paclitaxel (2 
µg/mm2 balloon surface) and polyethylene 
glycol, an excipient that facilitates drug transfer 
into the vessel wall. From July 2015 to November 
2017, 50 patients (41 M, 9F) were subject to 53 
PTA DCBs for femoro-popliteal lesions. All 
patients had the age >18 years, life expectancy>1 
year and were affected by lower limb ischemia 
classified as Rutherford class 3, 4 and 5. The 
angiographic criteria included de novo lesion 
>70% stenosis within the superficial femoral 
artery and/or popliteal artery down to the 
trifurcation, target reference vessel diameter 4 to 
6 mm, patent inflow artery and at least one patent 
tibioperoneal run-off vessel (7). According to the 
American Heart Association practice guidelines, 
the restenosis was defined as the focal systolic 
peak velocities (PSV)>300 cm/s, velocity ratio 
(Vr)>3.0, and uniform PSVs <50 cm/s (8). In 
forty-eight cases (85.7%) only an angioplasty 
with DCB was performed. Eight cases required 
additional procedures: four stents were deployed 
in the superficial femoral artery following DCB 
angioplasty PTA; two iliac stenting and two 
femoral endarterectomies were also necessary. 
After treatment, all patients underwent dual 
antiplatelet therapy (aspirin + clopidogrel) for six 
months. Follow-up included: clinic exam, Ankle-
Brachial Index (ABI) and duplex scan at 1, 3, 6, 
12 months and annually thereafter. 
 
 
III. PROCEDURE  
 
Three days prior to procedure patients received 
dual antiplatelet therapy, while a single dose of 
3500 U.I. of sodium heparin was administered 
intravenously upon placement of the long sheath 
during procedure. In forty-eight cases the 
procedures were performed under local 
anesthesia; in two cases, spinal anesthesia was 
given in order to perform a femoral 
endarterectomy. A retrograde contralateral 
femoral approach with a long reinforced sheath 
(6 Fr 45 cm, Destination - Terumo, Tokyo, Japan) 
was chosen in order to give more support and to 
perform selective angiography. Target vessel 
recanalization was carried out with a Berenstein 
or a Vertebral 4 Fr catheter and a standard soft 
0.035” guidewire or a 0.018’’ guidewire trying to 
remain within the true lumen whenever possible. 
A predilation of the target lesion was performed 
in all patients with an uncoated balloon 1 mm less 
than the reference vessel diameter to avoid drug 
dispersion during the lesion crossing. Size of the 
DCB was determined according to the diameter 
of the vessel based on preoperative ultrasound 
images in a one to one ratio. Inflation time of the 
DCB was at least 3 minutes. 
 
 
IV.  FOLLOW-UP AND ENDOPOINTS 
 
Clinical evaluations were made at 1, 3, 6 and 12 
months post-procedure with a Duplex ultrasound 
of the target lesions, ABI, and evaluation if any 
adverse events were present. Endpoints were 
primary patency and freedom from major adverse 
events (MAE) defined as limb amputation, death, 




V.  STATISTICAL ANALYSIS 
 
Statistical analysis was performed using SPSS 
20.0 for Windows (IBM Corp, Armonk, NY).  
Continuous data are expressed as mean ± 
standard deviation, categorical variables are 
expressed as counts and percentage while Kaplan 
– Meier estimates are presented for patency.  
 
 
VI.  RESULTS 
Mean age was 64 ± 7.4 years. Twenty-nine (58%) of 
patients were currently smokers, 66% had 
hyperlipidemia, 68% had diabetes, 64% were affected 
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with hypertension, 14% had chronic renal failure, 
76% had COPD and 42% CAD.  Based on clinical 
data: twenty-eight patients had severe claudication 
(56% - Rutherford class 3); seventeen patients 
suffered from ischemic rest pain (34% - Rutherford 
class 4); and five presented minor tissue loss (10% - 
Rutherford class 5). Forty-two percent (42%) of 
patients showed femoro-popliteal lesion TASC B, 
58% presented lesions belonging to TASC C. Lesions 
were located 1 cm distal to the femoral bifurcation and 
at least in 1 segment of the popliteal artery (mean 
length of lesions 89 ± 3.2mm). Angiography showed 
evidence of from 70 to 90% stenosis or total 
occlusions (18%). Superficial femoral artery (SFA) 
was involved in 82% of cases. Fifty-three DCBs were 
employed in 50 patients (mean length balloons 
91.1±33.8 mm; mean balloon diameter 4.9±0.7mm). 
In two cases two DCBs were used. Primary patency 
rate at 12 months as shown by Kaplan – Meyer 
survival estimates was 94% (Fig.1).  
 
 
Fig.1 94% primary patency rate at 12 months 
Freedom from major adverse events was 81.8% at 12 
months, as shown by Kaplan – Meier (Fig.2).  
 
                         
                
Fig.2 81.8% Freedom from MAE at 12 months 
 
The mean ABI increased by 0.35 from preoperative 
value of 0.59  0.1 to value postoperative 0.94  0.2 
at 1 month and remained elevated at 0.94  0.2 at 1 
year (p < 0.001).    All occlusions were patent at 12 
months. Additional procedures included: four lesions 
requiring a self-expandable stent following DCB due 
to residual stenosis >50% (ZilverFlexTM - Cook 
Medical, Bloomington, Indiana, U.S.A.) mean 
diameter 6±1 mm; middle length 103.3±40.4 mm); 
two lesions requiring iliac stenting [Dynamic 
(BIOTRONIK AG · Switzerland) 9x38 mm and 
ZilverFlex 8x80 mm in common iliac artery and 
Everflex (Medtronic/ Covidien, Mansfield, MA, 
USA) 7x60 mm in external iliac artery] and two 
lesions requiring an endarterectomy of the femoral 
bifurcation. Three restenosis occurred (two diabetic 
patients) after 12 months of follow – up which were 
treated with a second DCB. Two patients underwent 
major lower limb amputations, both suffering from 
diabetes. Three patients died and one was lost during 
follow – up. 
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VII. DISCUSSION  
 
 Restenosis after PTA or stenting of the femoro-
popliteal tract is a growing and challenging 
problem. The disease is histologically 
characterized by the marked presence of fibrin 
deposition and accumulation of macrophages and 
multinucleated foreign body giant cells as 
compared to coronary and carotid atherosclerotic 
disease, which are richer in necrotic core (9,10) 
The first randomized, controlled trials (RCTs) 
comparing DCB with Paclitaxel vs standard 
uncoated PTA were THUNDER (11), PACIFIER 
(12), FemPac (13) and LEVANT I (14). All 
showed greater effectiveness and safety of DCB 
over POBA and reported that significant 
improvements of clinical parameters compared to 
preoperative values had taken place after 6 and 12 
months (Rutherford classification and ankle-
brachial index). Predominance of DCB over PTA 
alone was also confirmed by these trials in a large 
meta-analysis study (15). 
Others clinical trials, LEVANT II study (Lutonix 
Paclitaxel – Coated Balloon for the Prevention of 
Femoropopliteal Restenosis) (5) and the 
IN.PACT SFA study (Randomized Trial of 
IN.PACT Admiral Drug Coated Balloon vs 
Standard PTA for the Treatment of SFA and 
Proximal Popliteal Arterial Disease) (6), 
evaluated two different DCBs. These balloons 
differ from each other in terms of excipient, 
paclitaxel dose and coating formulation. The 
Lutonix DCB with polysorbate/sorbitol and a 2 
µg/mm2 dose of paclitaxel showed a primary 
patency of 73.5% at 12 months, while the 
IN.PACT Admiral DCB with urea and a 
paclitaxel dose of 3.5 µg/mm2 showed a primary 
patency of 86.6% at 12 months.  
Recently published studies are the single – arm 
ILLUMENATE First-In-Human Study (16) and 
the ILLUMENATE Pivotal study (7) 
(prospective, randomized, single blind and multi-
center study). The Pivotal study reported a 
primary patency per Kaplan – Meier estimates of 
82.3% at 12 months in the DCB cohort vs 70.9% 
in PTA cohort.  The mean length of lesions 
treated in this study is comparable with the main 
studies: THUNDER (7.4 cm), LEVANT I (8.1 
cm), PACIFIER (7 cm) and IN.PACT SFA (8.94 
± 4.89cm).  
In our study occlusions were found to be 18% 
higher rates than in the ILLUMENATE FIH 
study (12.1%) but lower than in the other main 
studies mentioned above. All occluded lesions 
were patent through 12 months, which suggests 
adequate effectiveness of DCB in CTOs. On the 
contrary, in our study primary patency was 93.9% 
at 12 months, which is better than the LEVANT 
2 study (5) (73.5%) and comparable to the 
IN.PACT SFA study (6) (86.6%), 
ILLUMENATE FIH study (16) (89.5%) and 
ILLUMENATE Pivotal study (7) (82.3%).  In our 
own study stents were only used in bail-out 
situations such as in flow – limiting dissections 
(stenosis > 50%) which happened in four cases. 
Calcifications on DCB effectiveness has been 
reported in the literature (17) yet definitions of 
calcium severity are found to differ as calcium 
may act as a barrier to the absorption of paclitaxel 
and circumferential calcium has been shown to be 
a stronger predictor of failure than longitudinal 
calcifications (18). Nevertheless, it is recognized 
that calcified and longer lesions remain a 
challenging subset that is less responsive to 
DCBs, determining a high rate of provisional 
stents (19). Directional atherectomy (DA) 
removes plaque from the vessel wall providing 
improved luminal gain and plaque modification 
resulting in low rates of bail-out stenting, 
perforation, and dissection (19). 
The combination of DA plus DCB has been 
demonstrated to be safe and effective for long 
calcified lesions compared to treatment with 
DCB alone, however this has not yet been fully 
proven with an adequately powered randomized 
trial (20). 
In conclusion treatment with DCB is safe and 
effective and can be considered a first choice 
technique in non-complex de novo lesions of the 
femoro – popliteal tract (TASC B and C lesions). 
Differences across DCBs can be explained by 
technical features such as drug dose, coating 
formulation, and excipient. These features impact 
drug tissue release timing and maintenance of 
therapeutic levels, as well as drug wash-out and 
downstream embolization. Procedural variables 
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impact the effectiveness of the DCB. (7) The 
Stellarex DCB uses a 2 μg/mm2 paclitaxel dose 
combined with a polyethylene glycol (PEG) 
excipient. PEG is a polymer characterized by 
high molecular weight that results in durability of 
the drug coating, enabling it to be resistant to 
balloon deformation such as flexion and 
elongation. The combination of the hybrid 
coating and the durability of PEG is the basis of 
the drug transfer efficiency of the Stellarex DCB; 
the affinity of PEG for hydroxyapatite may 
maintain this transfer efficiency in the presence 
of calcified lesions and may explain the 
statistically superior primary patency of the 
Stellarex DCB over PTA (22), (23) 
 This study presents several limits: lack of a 
control arm, monocentric and retrospective study 
and the exclusion of post-PTAs and intrastent 
restenosis. But, our study, based upon mid-
term/21-month data, reveals a low rate of 
restenosis and all a year following procedure, 
thereby extending the time to restenosis. Longer-
term follow-up studies are recommended to 
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